FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

  • The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's FHTX Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). 
  • The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. 
  • Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that is believed to be on-target for the proposed mechanism of action for FHD-286. 
  • Also See: Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly.
  • The FDA has requested a review of the safety database, risk mitigation strategies, and clinical activity breakdown across dose levels.
  • Patients currently enrolled in the dose-escalation Phase 1 study of FHD-286 in AML/MDS and benefitting from treatment may continue to receive treatment. However, no new patients can be enrolled. 
  • The partial hold does not apply to the FHD-286 dose-escalation Phase 1 study in metastatic uveal melanoma.
  • Until Foghorn has resolved the partial clinical hold for the AML/MDS study, the company is suspending guidance on the timing of the data release for the dose-escalation phase of the FHD-286 program.
  • Price Action: FHTX shares closed 24.9% lower at $8.60 during after-hours trading on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!